SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

NATCO Pharma informs about closure of trading window

01 Apr 2023 Evaluate

NATCO Pharma has informed that the Trading Window for dealing in the securities of the Company would remain closed for the Directors, Designated Persons, their immediate relatives and all other connected persons covered in terms of the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time with effect from April 1, 2023 to till 48 hours after the declaration of the Financial Results of the Company for the quarter and year ended on March 31, 2023. The date of the Board Meeting for declaration of the financial results of the Company for the quarter and year ended on March 31, 2023 will be intimated in due course of time.

The above information is a part of company’s filings submitted to BSE.

Natco Pharma Share Price

1174.00 19.80 (1.72%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×